UF team plays major role in newly approved drug

A team of investigators led by pharmaceutical company Italfarmaco, in collaboration with the University of Florida, demonstrated that the first nonsteroidal drug for the treatment of Duchenne, a severe form of muscular dystrophy, is associated with slower functional decline and decreased fat replacement in muscle.

Learn more: UF team plays major role in success of newly approved Duchenne muscular dystrophy drug – UF Health